Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meredith M Regan

Showing results (111-120 of 260) with videos related to

Pageof 26
Sort By:
Breast (Edinburgh, Scotland)|July 4, 2012
A risk score based on histopathological features predicts higher risk of distant recurrence in premenopausal patients with lymph node-negative endocrine-responsive breast cancerSilvia Dellapasqua, Vincenzo Bagnardi, Meredith M Regan, et al.
Cancer|September 24, 2010
Elevated plasma tissue inhibitor of metalloproteinase-1 levels predict decreased survival in castration-resistant prostate cancer patientsWilliam K Oh, Roberto Vargas, Susanna Jacobus, et al.
Breast (Edinburgh, Scotland)|June 15, 2020
Estimation of historical control rate for a single arm de-escalation study - Application to the POSITIVE trialZhuoxin Sun, Samuel M Niman, Olivia Pagani, et al.
American Journal of Epidemiology|December 19, 2016
Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of HeterozygosityThomas P Ahern, Daniel L Hertz, Per Damkier, et al.
Cancer|January 20, 2009
Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapyToni K Choueiri, Wanling Xie, Anthony V D'Amico, et al.
Molecular Oncology|August 16, 2015
Genotyping concordance in DNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analysesDaniel L Hertz, Kelley M Kidwell, Jacklyn N Thibert, et al.
Human Genetics|June 5, 2003
Increased prevalence of CFTR mutations and variants and decreased chloride secretion in primary sclerosing cholangitisSunil Sheth, Julie C Shea, Michele D Bishop, et al.
The Journal of Urology|October 20, 2009
Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detectionStephen J Eyre, Donna P Ankerst, John T Wei, et al.
The New England Journal of Medicine|August 21, 2009
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer, Henning Mouridsen, Anita Giobbie-Hurder, et al.
Cancer Prevention Research (Philadelphia, Pa.)|March 4, 2011
Association of prostate cancer risk Loci with disease aggressiveness and prostate cancer-specific mortalityMark M Pomerantz, Lillian Werner, Wanling Xie, et al.
Pageof 26

Showing results (111-120 of 260) with videos related to

Sort By:
Pageof 26
Breast (Edinburgh, Scotland)|July 4, 2012
A risk score based on histopathological features predicts higher risk of distant recurrence in premenopausal patients with lymph node-negative endocrine-responsive breast cancerSilvia Dellapasqua, Vincenzo Bagnardi, Meredith M Regan, et al.
Cancer|September 24, 2010
Elevated plasma tissue inhibitor of metalloproteinase-1 levels predict decreased survival in castration-resistant prostate cancer patientsWilliam K Oh, Roberto Vargas, Susanna Jacobus, et al.
Breast (Edinburgh, Scotland)|June 15, 2020
Estimation of historical control rate for a single arm de-escalation study - Application to the POSITIVE trialZhuoxin Sun, Samuel M Niman, Olivia Pagani, et al.
American Journal of Epidemiology|December 19, 2016
Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of HeterozygosityThomas P Ahern, Daniel L Hertz, Per Damkier, et al.
Cancer|January 20, 2009
Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapyToni K Choueiri, Wanling Xie, Anthony V D'Amico, et al.
Molecular Oncology|August 16, 2015
Genotyping concordance in DNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analysesDaniel L Hertz, Kelley M Kidwell, Jacklyn N Thibert, et al.
Human Genetics|June 5, 2003
Increased prevalence of CFTR mutations and variants and decreased chloride secretion in primary sclerosing cholangitisSunil Sheth, Julie C Shea, Michele D Bishop, et al.
The Journal of Urology|October 20, 2009
Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detectionStephen J Eyre, Donna P Ankerst, John T Wei, et al.
The New England Journal of Medicine|August 21, 2009
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer, Henning Mouridsen, Anita Giobbie-Hurder, et al.
Cancer Prevention Research (Philadelphia, Pa.)|March 4, 2011
Association of prostate cancer risk Loci with disease aggressiveness and prostate cancer-specific mortalityMark M Pomerantz, Lillian Werner, Wanling Xie, et al.
Pageof 26